Skip to main content
UCL Ventures Navigate back to homepage
Find your Business Manager

Main navigation

  • Your route to market

    Your route to market

    We guide UCL academics, researchers and clinicians to get their research to market.

    Disclose an idea
    • Getting started An introduction to commercialisation and next steps
    • Our collaborative approach How we work with you to get to market
    • What you can expect Demystifying the process of commercialisation
    • Options to move forwards Explore the different pathways to market
      • Protect your idea
      • Create a company
      • Licensing your invention
      • Routes to social impact
    • Funding & support The financial and practical help that we can offer
      • Help managing your project
      • Training & tools
      • Common questions
  • Explore innovations

    Explore innovations

    Our portfolio and technologies span AI and quantum, to gene therapies to consumer products.

    • Current page: Spinout portfolio Browse our portfolio of spinout companies, based on UCL research
    • Our expertise & pipeline The sectors we span and therapeutics in development
    • Social Ventures Ventures driving impact in communities
    • License a technology Opportunities & collaborations with UCL's world-class research
  • Global impact

    Global impact

    How UCL research is changing the way the world lives, works and thrives.

    • Inspiring stories Real-world impact and successes, supported by UCL Ventures
    • Impact Report Our annual report showcases how UCL research is going beyond the university
    • Supporting innovation at UCL Understand our role in the innovation ecosystem
  • Investors & business

    Investors & business

    Opportunities for collaboration across UCL's world-class research.

    • Why partner with UCL Ventures With over 30 years in commercialisation, we have a strong track record
    • Our portfolio View our spinout companies across all sectors
  • News & events

    News & events

    The latest news and events from our team and portfolio.

    • News & views Stay up to date with the latest insights and announcements
    • Events Where you can find us across UCL and external events
  • Get in touch

    Get in touch

    Contact our team of experts for all your queries and needs.

    • Speak to the team Choose your enquiry type to reach the right team
Find your Business Manager

EpilepsyGTx

This UCL Ventures spinout focuses on cutting-edge treatments for focal refractory epilepsy.

3d rendered image of neuron cell network on black background

Breadcrumb trail

  1. Home
  2. Spinout portfolio
  3. EpilepsyGTx

EpilepsyGTx is a late preclinical-stage biotech, developing cutting-edge gene therapies that will transform the management of focal refractory epilepsy (FRE).

The spinout's goal is to make patients with FRE seizure-free. 

Epilepsy is one of the most common neurological diseases, affecting over 50 million people worldwide (WHO). Focal epilepsy is a group of disorders in which patients experience seizures that arise from a specific part of the brain, while refractory epilepsy occurs when seizures persist despite trials of at least two tolerated and appropriately chosen antiseizure treatments.

Approximately one in five patients with epilepsy has focal refractory epilepsy.  

The mortality in people with refractory epilepsy is four times higher than in the general population. In the UK alone, approximately 1,000 epilepsy-related deaths are recorded each year. The hallmark symptom of FRE is recurrent and unpredictable seizures, which can cause injury and become life-threatening. 

People with epilepsy often struggle with anxiety, depression, and the social stigma associated with their disease, and their professional life is severely restricted.

The EpilepsyGTx journey so far: 

  • 2024: EpilepsyGTx raised $10 million seed funding  
  • 2025: A $33 million Series A followed in 2025

 

The Epilepsy GTx team
The EpilepsyGTx team from UCL: Prof Stephanie Schorge; Prof Dimitri Kullmann; Prof Matthew Walker; Prof Gabriele Lignani,  

Our people

Team

No results found, try another search term.

Dr Lorenzo Schiazza

Project Manager

Dr Schiazza has been supporting the delivery of projects both in the Biopharm and the Physical sciences field, ranging from cell and gene therapies for ocular diseases to waterproof coatings, to viral vectors.

Lorenzo holds a PhD in Advanced Therapeutics and Nanomedicines from the University of Nottingham, and focused on polymers for oral drug delivery. He joined the Project Management team in 2024.

  • LinkedIn

Louise Hammond

Director of Operations

Louise joined the UCL Ventures team having worked for the company in a consultancy capacity prior to this. As Director of Operations, Louise manages the Project Management team, Human Resources & Payroll, Information Technology, Estates Management and Admin. During her time at UCL Ventures, she has held the positions of Deputy Director of Finance and Head of Operations.

Louise has many years of experience in finance – joining UCL Ventures from the Finance Division of UCL.

She holds qualifications from the Chartered Institute of Management Accountants and the Chartered Management Institute.

Lucy Armstrong

Board of Directors

Lucy has spent over 30 years working with mid-corporate businesses to accelerate their development and success by focusing on stakeholder and management development and succession. 

Her
experience ranges from funding start up and early-stage manufacturing businesses in the North East through to mergers and disposals of international operations. The organisations she is currently engaged with include Holker Estates, Mobeus VCT plc, Cyberhawk Innovations and The Drinkaware Trust, the alcohol education charity.

She has chaired Port of Tyne since 2017 and is a member of the Maritime Skills Commission.  Her early career was in private equity, corporate development and headhunting with 3i plc, Courtaulds Textiles and Tyzack.  She is a former chair of the National Enterprise Research Centre, focused on the study of growth in private and family businesses and Northumbria University.

Lucy was educated at Oxford University and holds an MBA and an MSc in forensic psychology and criminology. She continues to chainsaw, scuba dive and ring church bells.

Image of Lucy

Lucy Tuffin

Digital Marketing & Communications Executive

Lucy is responsible for our digital marketing efforts, overseeing the company website and social media channels. Prior to joining UCL Ventures in 2017, she gained a BSc (Hons) degree in Business Management, as well as experience in marketing and PR-focused roles.

Marina Santilli

Interim Director of Physical Sciences & Engineering

Marina has specialised in the commercialisation of computer science and AI-based inventions and deep tech venture building since joining UCL Ventures in 2007. She headed straight into industry after graduating in Physics from Imperial College, enjoying a successful career in datacomms engineering and becoming Director of new product development at Verizon.

In 2010 she designed and developed E-lucid, a platform to enable online licensing of UCL’s intellectual property. E-lucid is now used by over 30 research institutions around the world and was spun out as a commercial business in 2023.

Marina was involved in the formation of many successful UCL spinouts including Satalia, Re:infer, 3DRepo, MatrixMill, Humanloop, Stanhope AI.

Dr. Mark Fisher

Associate Director

Dr Fisher has management responsibility for the BioPharm patent portfolio and strategic business support for the BioPharm team. At the coalface, Mark manages the commercialisation of technology from the Institute of Ophthalmology and Moorfields Eye Hospital UCL Global Business School for Health and the Department of Ageing, Arthritis and Regenerative Medicine.

He holds a first degree in Industrial Biology and a PhD in Biochemistry and Molecular Biology from UCL, in association with one of the first biotechnology companies to be established in the academic sector.

Mark brings more than 30 years of experience in life sciences and healthcare licensing, new company development and securing investment from both the public and private sectors to his team. To date, Mark has been responsible for the establishment of more than 25 new businesses in diagnostics, drug discovery, medical devices and therapeutics.

As a certified lead auditor of ISO 13485, Dr Fisher has additional experience in quality management systems and the translation of technologies from research and design into manufacture at home and abroad.

Mark is a Freeman of the Worshipful Company of Management Consultants and gained the Freedom of the City of London in 2010 for his contribution to the economy through new business development.

  • LinkedIn

Michelle Huggins

Head of People Services

Michelle's responsibilities include managing the HR, payroll and pensions functions, together with payments and IR35 compliance. Prior to joining UCL Ventures in 2011, Michelle was the Payroll Manager for UCL.

She has a diploma in payroll management, is qualified as a workplace mediator and holds a CIPD Intermediate Diploma in human resources management. She is also an associate member of the CIPD and a full member of the CIPP.

Narpal Sihra

Project Manager

With extensive experience in the UK Life Sciences sector, Narpal has delivered large-scale Knowledge Transfer Programmes as part of the Project Management team.

Throughout her career, Narpal has
played a key role in connecting businesses with funding opportunities and strengthening partnerships between industry and academia.

Narpal joined us in 2024 and holds a BA (Hons) in Business Studies with a focus on Marketing from the University of Westminster, in addition to an APM Project Fundamentals Qualification and completion of the Management Development Programme from the Institute of Leadership and Management.

  • LinkedIn

Naseem Staunton

Legal Counsel

Naseem is a commercial contracts lawyer with particular experience in technology transfer agreements and other IP matters at UCL Ventures. Prior to joining UCL Ventures, Naseem spent several years working in private practice before joining a private equity company and then, most recently, the commercial legal team of another London university.

  • « First
  • ‹ Previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Current page 5
  • Page 6
  • Page 7
  • Page 8
  • Next ›
  • Last »
EpilepsyGTx logo

Team

Professor Dimitri Kullman

Chief Scientific Officer; Scientific Founder

He is part of the Queen Square Institute of Neurology.

  • UCL Profile

Professor Stephanie Schorge

Scientific Founder

Stephanie is the Sophia Jex-Blake Professor of Neuroscience at UCL and the Head of the Research Department of Neuroscience, Physiology and Pharmacology (NPP). She has been at UCL since 1999.

Prof Matthew Walker (UCL Institute of Neurology)

Prof Gabriele Liagnani (UCL Institute of Neurology)

Caitriona O'Rourke

Dr. Caitriona O'Rourke (Away from office)

Senior Business Manager

Dr O’Rourke joined us in 2018, having worked as a research associate within UCL on several diverse life science / pharmaceutical research projects covering the areas of tissue engineering, drug delivery, regenerative medicine, biomaterials and stem cell biology.

Caitriona holds a PhD in tissue engineering from the Open University and a MSc in neuropharmacology from the National University of Galway, Ireland.

UCL Ventures footer

About UCL Ventures

  • Our people
  • What we do
  • Who we are
  • Our culture

Forms & Resources

  • Publications and downloads

Accreditations

  • Cyber essentials
    cyber essentials logo
  • Living wage
    living wage employer logo
UCL Ventures

UCL Ventures Limited (Company Registration No: 02776963) is a wholly-owned subsidiary of University College London. 

Registered office: 
University College London
Gower Street
London
WC1E 6BT

UCL social media menu

  • Link to Linkedin
Back to top

Legal

  • Cookie policy
  • Freedom of information
  • Privacy policy
  • Rules of website use

© 2026 UCL Ventures Limited